New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

June 15, 2017

The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 show that in postmenopausal women with osteoporosis, 12 months of treatment with romosozumab is associated with large, rapid reductions in their risk of a vertebral fracture compared to placebo.

In those women receiving romosozumab, all clinical vertebral occurred in the first two months of treatment; overall, the risk of a vertebral fracture was more than five times greater in the group of women given placebo.

"These results support this new class of drug as a highly effective treatment for postmenopausal women who have osteoporosis with established (BMD) deficit who are at increased risk of fracture," said Professor Piet Geusens, lead author from Maastricht University, The Netherlands. "The rapid and large reduction in clinical vertebral fracture risk is an important and highly relevant clinical outcome," he added.

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin (a glycoprotein produced by bone cells). This action has the dual effect of increasing bone formation and decreasing bone resorption, resulting in significant increases in BMD. Previous studies have shown that romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular and cortical compartments of the spine and hip regions.

The Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) is an international, randomised, double-blind, placebo-controlled, parallel-group trial. FRAME enrolled 7,180 postmenopausal women, 55-85 years old, with evidence of osteoporosis confirmed by abnormally low density scores in their spine, hip, and femoral neck, but no severe vertebral fracture. Patients received monthly romosozumab (n=3,589) or placebo (n=3,591) for 12 months.

Initial results from FRAME had shown romosozumab was associated with a lower risk of new vertebral fractures than placebo at 12 months. The effect of romosozumab on the risk of vertebral fracture was rapid, with only 2 additional vertebral fractures (of a total of 16 such fractures in the romosozumab group) occurring in the second 6 months of therapy.

These new data from FRAME focussed on the incidence of clinical vertebral fracture in those women in the study who developed back pain consistent with this diagnosis. Monthly study visits in FRAME enabled timely X-ray confirmation of any suspected clinical vertebral fracture.

Of those 119 women reporting back pain over 12 months, 20 were diagnosed with a new or worsening vertebral fracture. In the romosozumab group, there were 3 clinical vertebral fractures (<0.1% of patients and all in the first 2 months) identified compared to 17 (0.5%) with placebo. Clinical vertebral fracture risk was 83% lower in the romosozumab group vs. placebo at 12 months. In women with clinical vertebral fracture vs. no clinical , measurements of BMD showed more severe osteoporosis; however, other baseline characteristics were comparable among all women who reported back pain in both treatment groups.

Postmenopausal osteoporosis is considered a serious public health concern due to its high prevalence worldwide. Approximately 30% of all have osteoporosis in Europe and the US; at least 40% of these women will go on to sustain one or more fragility fractures in their lifetime.

The most common fractures associated with postmenopausal osteoporosis occur at the hip, spine and wrist. Of particular concern are vertebral (spinal) and hip fractures. Vertebral fractures can result in intense back pain and deformity.

Explore further: Romosozumab significantly increases bone mineral density and bone content compared with teriparatide

Related Stories

Romosozumab significantly increases bone mineral density and bone content compared with teriparatide

June 11, 2014
A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content ...

Abaloparatide may help prevent fractures in postmenopausal women with osteoporosis

April 3, 2016
The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup ...

Investigational osteoporosis drug, abaloparatide, lowers fracture risk

March 6, 2015
Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant ...

Romosozumab increases bone mineral density post-menopause

January 6, 2014
(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the New England Journal of Medicine.

Injected drug reduces risk of fracture among women with osteoporosis

August 16, 2016
Among postmenopausal women with osteoporosis at risk of fracture, daily injection of the drug abaloparatide for 18 months significantly reduced the risk of new vertebral and nonvertebral fractures compared with placebo, according ...

Osteoporosis screening and treatment fall short for women with hip fractures

February 23, 2017
It's important to identify and treat osteoporosis following hip fracture, but a large study found low rates of assessment and treatment in postmenopausal women who had suffered a hip fracture.

Recommended for you

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.